Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
PHA-543613 is an agonist of α7 nicotinic acetylcholine receptors (nAChRs).1,2 It is selective for α7 nAChRs over α4β2-, α4β4-, α3β2-, or α3β4 subunit-containing nAChRs and the serotonin (5-HT) receptor subtype 5-HT3 (EC50s = 0.03, >100, >50, >100, >100, and 11 µM, respectively, in calcium mobilization assays).2 PHA-543613 prevents decreases in the number of retinal ganglion cells in a rat model of glaucoma when applied topically.3 It improves sensorimotor deficits and reduces brain edema in a mouse model of intracerebral hemorrhage, effects that can be reversed by methyllycaconitine (Item No. 21398) or wortmannin (Item No. 10010591).4 PHA-543613 (1 mg/kg) increases the time spent with the novel object in the novel object recognition test and reverses amphetamine-induced auditory gating deficits in rats.1 Intracerebroventricular administration of PHA-543613 (0.1 mg/animal) reduces food intake and body weight in rats.5
WARNING This product is not for human or veterinary use.
1. Discovery of N-
2. Pharmacological effects of nonselective and subtype-
3. Prevention of glaucoma-
4. PHA-
5. The alpha-